360 related articles for article (PubMed ID: 32144955)
1. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
3. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
4. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study.
Ilic K; Song I; Wu J; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1260-1270. PubMed ID: 32506738
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
[TBL] [Abstract][Full Text] [Related]
8. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
9. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
Stier B; Fossler M; Liu F; Caltabiano S
Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
[TBL] [Abstract][Full Text] [Related]
10. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.
Parkinson J; Dota C; Källgren C; Gottfridsson C; Bjursell M; Perl S; Kӧrnicke T; Rekić D; Johansson S
Br J Clin Pharmacol; 2023 Jun; 89(6):1747-1755. PubMed ID: 36504291
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
[TBL] [Abstract][Full Text] [Related]
12. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
13. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
14. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects.
O'Donnell J; Maloney K; Steidler M; Morrison R; Isaacs R
Clin Transl Sci; 2021 Jul; 14(4):1423-1430. PubMed ID: 33934519
[TBL] [Abstract][Full Text] [Related]
16. Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
Newman LM; Kankam M; Nakamura A; Conrad T; Mueller J; O'Donnell J; Osborn BL; Gu K; Saviolakis GA
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0129221. PubMed ID: 34606332
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
de Jong J; Hellemans P; Jiao JJ; Huang Y; Mesens S; Sukbuntherng J; Ouellet D
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1227-1237. PubMed ID: 29080970
[TBL] [Abstract][Full Text] [Related]
18. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
19. Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants.
Lissy M; Demmel V; Sachse R; Ammer N; Kelepouris N; Ostrow V
Clin Pharmacol Drug Dev; 2021 May; 10(5):494-501. PubMed ID: 32961034
[TBL] [Abstract][Full Text] [Related]
20. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
